Wegovy® (semaglutide) is an FDA-approved, once-weekly injectable medication specifically designed to support chronic weight management in adults who are overweight or obese. Developed by Novo Nordisk, Wegovy has revolutionized weight loss treatment by targeting the body’s appetite regulation and insulin response mechanisms.

It is intended for adults with:

• A BMI of 30 or greater (obesity)

• Or a BMI of 27 or greater (overweight) with at least one weight-related medical condition such as high blood pressure, type 2 diabetes, or high cholesterol

Wegovy® for Weight Loss – What You Need to Know

How Wegovy® Works

Wegovy® contains semaglutide, a GLP-1 receptor agonist, which mimics a naturally occurring hormone in the body that:

• Increases insulin secretion

• Reduces appetite

• Slows gastric emptying (how quickly food leaves the stomach)

• Helps regulate blood sugar levels

By working through these pathways, Wegovy helps you feel full longer, eat less, and lose weight effectively when combined with a reduced-calorie diet and increased physical activity.

Efficacy and Results

Clinical trials have shown that Wegovy can help patients lose an average of 15% of their starting body weight over 68 weeks when combined with diet and exercise.

Key findings from the STEP clinical trial program include:

• 83.5% of patients lost ≥5% of body weight

• 66% lost ≥10% of body weight

• 50.5% lost ≥15% of body weight

These results have positioned Wegovy as one of the most effective FDA-approved medications for weight loss to date.